ALZHEIMER’S DISEASE (AD) EARLY DETECTION TECHNOLOGY
Lack of early
diagnosis and treatment of Alzheimer’s disease
- Epigenetic (mtDNA) based Biomarkers for early AD diagnosis
- Biomarker for the prediction of treatment response in AD patients
Optimizing patients' recruitment in clinical trials
Early AD detection in the clinical practice
Test based in blood biomarkers
All clinical trials have failed because patients' recruitment has been performed at advance stages of the disease. Therefore, Pharmaceutical Companies are our potential clients at short-term, in order to optimize patients' recruitment in current clinical trials, as well as, to reanalyze finished clinical trials in order to identify effective drugs that have been discarded As a second step, the technology should be easily introduced in national health systems and private medical insurances.
The group has robust data on the target validation obtained in the lab. It also has non-regulatory preclinical studies and first clinical proof-of-concept of target.
IP status: patent ongoing in national phases
IDIBELL is seeking a company partner to further develop the technology
through a co-development and investment